Kiromic BioPharma, Inc. (KRBP)
USD 0.08
(-2.33%)
USD 0.08
(-2.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 12.33 Million USD | 40.77% |
| 2022 | 8.76 Million USD | 135.2% |
| 2021 | -24.89 Million USD | -157.16% |
| 2020 | -9.68 Million USD | -401.92% |
| 2019 | -1.92 Million USD | -401.98% |
| 2018 | -384.3 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 9.9 Million USD | -19.72% |
| 2024 Q2 | 9.19 Million USD | -7.22% |
| 2023 Q3 | 6.97 Million USD | -5.79% |
| 2023 Q2 | 7.39 Million USD | -25.37% |
| 2023 FY | 12.33 Million USD | 40.77% |
| 2023 Q1 | 9.91 Million USD | 13.11% |
| 2023 Q4 | 12.33 Million USD | 77.0% |
| 2022 Q3 | 1.74 Million USD | 142.58% |
| 2022 Q2 | -4.08 Million USD | 67.57% |
| 2022 FY | 8.76 Million USD | 135.2% |
| 2022 Q1 | -12.61 Million USD | 49.36% |
| 2022 Q4 | 8.76 Million USD | 403.34% |
| 2021 Q1 | -7.1 Million USD | 26.59% |
| 2021 FY | -24.89 Million USD | -157.16% |
| 2021 Q4 | -24.89 Million USD | 29.19% |
| 2021 Q3 | -35.16 Million USD | -1080.4% |
| 2021 Q2 | -2.97 Million USD | 58.09% |
| 2020 Q3 | -363.7 Thousand USD | 76.8% |
| 2020 Q2 | -1.56 Million USD | 48.47% |
| 2020 FY | -9.68 Million USD | -401.92% |
| 2020 Q1 | -3.04 Million USD | -57.72% |
| 2020 Q4 | -9.68 Million USD | -2562.22% |
| 2019 Q4 | -1.92 Million USD | 0.0% |
| 2019 FY | -1.92 Million USD | -401.98% |
| 2018 FY | -384.3 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| America Great Health | 1.81 Million USD | -579.387% |
| Ampio Pharmaceuticals, Inc. | -3.81 Million USD | 423.421% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | -883.931% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 61.7% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | 1414.004% |
| Better Therapeutics, Inc. | -860 Thousand USD | 1534.709% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 151.875% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | -3656.687% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | -169.989% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 311.892% |
| Evelo Biosciences, Inc. | 3.19 Million USD | -285.819% |
| Evolutionary Genomics, Inc. | 3.16 Million USD | -289.635% |
| Finch Therapeutics Group, Inc. | 5 Million USD | -146.671% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 90.795% |
| Innovation1 Biotech Inc. | 179.15 Thousand USD | -6787.245% |
| Molecular Templates, Inc. | 707 Thousand USD | -1645.191% |
| Navidea Biopharmaceuticals, Inc. | 438.44 Thousand USD | -2714.156% |
| NexImmune, Inc. | -3.13 Million USD | 493.743% |
| Orgenesis Inc. | 21.78 Million USD | 43.36% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | -371.655% |
| Point of Care Nano-Technology, Inc. | -498.00 USD | 2477710.442% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 361.928% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | 10004.475% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 88.871% |
| Statera Biopharma, Inc. | 14.41 Million USD | 14.413% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 262.434% |
| Trevena, Inc. | 2.25 Million USD | -446.435% |
| Vaxxinity, Inc. | 10.13 Million USD | -21.778% |
| Vaccinex, Inc. | -1.28 Million USD | 1057.958% |
| Vicapsys Life Sciences, Inc. | 344.44 Thousand USD | -3482.129% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 6.802% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | -17045.855% |